Question | Discussion | References | CME Credit

Case 5: References

  1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-8.
    [The following link will open in a new window. PubMed Abstract]
  2. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160:2050-6.
    [The following link will open in a new window. PubMed Abstract]
  3. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet. 1998;352:1031-2.
    [The following link will open in a new window. PubMed Abstract]
  4. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32:403-25.
    [The following link will open in a new window. PubMed Abstract ]
  5. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 2002;41:1195-211.
    [The following link will open in a new window. PubMed Abstract ]
  6. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-77.
    [The following link will open in a new window. PubMed Abstract]
  7. Aberg JA, Rosenkranz SL, Fichtenbaum CJ, Alston BL, Brobst SW, Segal Y, Gerber JG; ACTG A5108 team. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS. 2006;20:725-9.
    [The following link will open in a new window. PubMed Abstract]
  8. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45:3445-50.
    [The following link will open in a new window. PubMed Abstract]
  9. Carr TA, Andre AK, Bertz RJ, et al. Concomitant administration of ABT-378/ritonavir. Results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin. 40th ICAAC, Toronto, September 2000, presentation 1644.
  10. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22:441-57.
    [The following link will open in a new window. PubMed Abstract]
  11. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94:1140-6.
    [The following link will open in a new window. PubMed Abstract]
  12. Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS. 2003;17:207-10.
    [The following link will open in a new window. PubMed Abstract]
  13. Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care STDS. 2000;14:13-8.
    [The following link will open in a new window. PubMed Abstract]
  14. Cheng CH, Miller C, Lowe C, Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm. 2002;59:728-30.
    [The following link will open in a new window. PubMed Abstract]
  15. Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis. 2002;35:e111-2.
    [The following link will open in a new window. PubMed Abstract]
  16. Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am J Med. 2002;112:505.
    [The following link will open in a new window. PubMed Abstract]
  17. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-27.
    [The following link will open in a new window. PubMed Abstract]

[Back to Case 5 Question | Back to Discussion]

CME Credit | Back to Top